Search clinical trials for: Regorafenib (BAY73-4506, Stivarga)

Total 170 results

Bayer

Completed

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy (REGARD)

Colorectal Neoplasms

Turkey
Bayer

Completed

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Neoplasms

Canada, United States
Bayer

Completed

Regorafenib Phase I Study in Mainland Chinese Patients

Oncology

China
Bayer

Completed

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Neoplasms

Hong Kong, Singapore
Bayer

Completed

Stivarga Regulatory Post-Marketing Surveillance Study in Korea (StivargaPMS)

Colorectal Neoplasms

Korea, Republic of
Bayer

Completed

Regorafenib Post-marketing Surveillance in Japan

Gastrointestinal Stromal Tumors

Japan
Bayer

Completed

Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer (REGO-ACT)

Colorectal Neoplasms

Austria
Bayer

Completed

Stivarga Real Life Evidence in Hungary

Colorectal Neoplasms

Hungary
Bayer

Completed

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Pharmacokinetics | Dietary Fats

United States
Bayer

Completed

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Metastatic Colorectal Cancer

India
Bayer

Not yet recruiting

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Advanced Gastrointestinal Stromal Tumor

United States
Bayer

Recruiting

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Solid Malignant Tumors

Taiwan, Japan, Korea, Republic of, France, India, Spain
Bayer

Completed

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States (COLONGER)

Metastatic Colorectal Cancer

United States
Bayer

Completed

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Carcinoma, Renal Cell

United States, France, United Kingdom, Finland, Germany, Poland
Bayer

Completed

Regorafenib Post-marketing Surveillance

Colorectal Neoplasms

Japan
Bayer

Completed

Safety and Effectiveness of Regorafenib (Correlate)

Neoplasms

Austria, Czechia, Switzerland, Italy, France, Mexico, Singapore, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Argentina
Bayer

Completed

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Neoplasms

United States
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Bayer

Completed

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib (COLONG)

Colorectal Neoplasms

Belgium
Bayer

Terminated

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes? (SMART)

Physician Education

United States
Bayer

Terminated

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Neoplasms

United States
Bayer

Completed

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Liver Neoplasms

United States, Canada, Japan, Spain, Sweden, Belgium, Argentina, Austria, Greece, Italy, Korea, Republic of, Netherlands, Russian Federation, Taiwan, Turkey, China, Denmark, Egypt, France, Saudi Arabia, Thailand
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct

United States
Bayer

Completed

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE)

Carcinoma, Hepatocellular

France, Spain, China, Switzerland, United States, Singapore, Germany, Russian Federation, Taiwan, Austria, Czechia, United Kingdom, Korea, Republic of, Australia, Hungary, Italy, Netherlands, Japan, Belgium, Brazil, Argentina
Bayer

Completed

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Colorectal Neoplasms

Brazil
Bayer

Terminated

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy (COAST)

Colorectal Neoplasms

Belgium, France, Spain, China, United States, Canada, Germany, Portugal, Japan, Israel, United Kingdom, Italy, Australia, Brazil
Bayer

Active, not recruiting

A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment (RegoSeq)

Metastatic Colorectal Cancer

Spain, Italy, France
Bayer

Completed

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)

Gastrointestinal Stromal Tumors

Belgium, Canada, Spain, United States, Finland, Korea, Republic of, Austria, United Kingdom, Italy, China, Israel, France, Poland, Germany, Netherlands, Japan, Singapore
Bayer

No longer available

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN)

Colorectal Neoplasms

France, Belgium, Spain, United States, Canada, Switzerland, Germany, Russian Federation, Australia, Austria, Israel, Italy, Mexico, Netherlands, Norway, United Kingdom, Poland, Hungary, Denmark, Portugal, Finland, Sweden, Ireland, Greece and more
Eureka Therapeutics Inc.

Recruiting

T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3)

Hepatocellular Carcinoma | Liver Neoplasm | Metastatic Liver Cancer | Liver Cancer, Adult

United States
Bayer

Terminated

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment (SORAGO-HCC)

Hepatocellular Carcinoma

Germany
Bayer

Completed

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (CONCUR)

Colorectal Neoplasms

China, Hong Kong, Taiwan, Vietnam, Korea, Republic of
Bayer

Completed

Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Tumors

Japan
Bayer

Completed

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

Colorectal Neoplasms

Germany
Bayer

Completed

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Metastatic Colorectal Cancer

Belgium, Italy, Spain, Canada, Japan, Czech Republic, United States, Australia, France, Hungary, China, Germany, Israel, Netherlands, Turkey, Portugal, Brazil, Switzerland, Argentina
Bayer

Completed

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Neoplasms

United States
Bayer

Completed

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib (ROCURS)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection | Malignant Solid Tumors

United States
Bayer

Completed

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy (RECORA)

Colorectal Neoplasm

Germany
Bayer
Merck Sharp & Dohme LLC

Completed

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Carcinoma, Hepatocellular

United States, Germany
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal Adenocarcinoma

United States
Bayer

No longer available

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

Gastrointestinal Stromal Tumors
Bayer

No longer available

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Gastrointestinal Stromal Tumors
Northwestern University
National Cancer Institute (NCI); Bayer

Completed

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Angiosarcoma

United States
Great Novel Therapeutics Biotech & Medicals Corporation

Recruiting

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Bayer
Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd

Active, not recruiting

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Solid Tumors

United States, United Kingdom, Belgium, France, Taiwan, Japan, Italy, Korea, Republic of
Bayer

Completed

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Neoplasms

Germany
University of Southern California
National Cancer Institute (NCI)

Completed

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid Tumor

United States
Bayer

Completed

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Solid Cancer

Germany, Italy, United States, Japan, United Kingdom
Bayer
Bristol-Myers Squibb

Completed

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Colorectal Cancer

United States
Humanity & Health Medical Group Limited

Recruiting

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Hepatocellular Carcinoma

Hong Kong

3

Subscribe